Form 4: Insider Sells Shares of ANI Pharmaceuticals
Statement of Changes in Beneficial Ownership
Thomas Andrew Rowland, SVP of ANI Pharmaceuticals, reported a sale of 459 shares of common stock on May 12, 2026.
Summary
- Thomas Andrew Rowland, Senior Vice President, Head of Established Brands at ANI Pharmaceuticals, Inc., reported a transaction involving company stock.
- On May 12, 2026, Rowland sold 459 shares of common stock at a price of $79.21 per share.
- Following this transaction, Rowland beneficially owns 38,271 shares of common stock directly.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to an insider selling shares, although the amount is relatively small and the filing is a routine disclosure.
Negatives
- An insider, Thomas Andrew Rowland, sold a portion of his holdings in ANI Pharmaceuticals.
Future Outlook
No forward-looking statements or guidance were provided in this filing.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not inherently signal company performance, but significant insider selling can sometimes be interpreted as a negative signal by the market.
Stakeholder Impact
- Shareholders may view insider selling with caution, potentially impacting short-term stock sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/12/2026 | Transaction Date (Sale of common stock by Thomas Andrew Rowland) |
| 05/13/2026 | Date of Report Filing |
Keywords
ANI Pharmaceuticals, ANIP, Insider Trading, Form 4, Stock Sale, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.